Alzhraa Alkhatib

Alzhraa Alkhatib

Auto-generated profile, based on publicly available information

Alzhraa Alkhatib

Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen El-Kom, Menoufia, Egypt

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
CCCaroline R Cartlidge
Caroline R Cartlidge
MUM R Abellona U
M R Abellona U
AAAlzhraa M A Alkhatib
Alzhraa M A Alkhatib
STSimon D Taylor-Robinson
Simon D Taylor-Robinson
Hepatocellular carcinoma (HCC) is the fifth most common malignancy, the third most common cause of cancer death, and the most common primary liver cancer. Overall, there is a need for more reliable biomarkers for HCC, as those currently available lack sensitivity and specificity. For example, the current gold-standard biomarker, serum alpha-fetoprotein, has a sensitivity of roughly only 70%. Cancer cells have different characteristic metabolic signatures in biofluids, compared to healthy cells; therefore, metabolite analysis in blood or urine should lead to the detection of suitable candidates for the detection of HCC. With the advent of metabonomics, this has increased the potential for new biomarker discovery. In this article, we look at approaches used to identify biomarkers of HCC using proton nuclear magnetic resonance (1H-NMR) spectroscopy of urine samples. The various multivariate statistical analysis techniques used are explained, and the process of biomarker identification is discussed, with a view to simplifying the knowledge base for the average clinician.

1 October 2025 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
AAAhmed Attia
Ahmed Attia
EEEsam Elshimi
Esam Elshimi
ZEZeinab Seif Eldin
Zeinab Seif Eldin
MRMohamed Akl Rady
Mohamed Akl Rady
AAAlzhraa Alkhatib
Alzhraa Alkhatib
IWImam Waked
Imam Waked
Background: Predicting the prognosis of patients with HCC is challenging. Aim: To evaluate the Assessment for Retreatment with TACE (ART) score in predicting survival after TACE retreatment and the value of adding post-TACE thrombocytopenia in improving its accuracy (P-ART). Methods: Barcelona Clinic Liver Cancer (BCLC) stages A and B patients underwent TACE retreatment, and records were reviewed. Radiologic tumor response (RTR) after the first TACE was considered a partial response, while the absence of response is a stable or progressive disease. The one year overall survival (OS) from the second TACE was determined. Results: One hundred and sixty patients included 88.1% men, age 60.7± 7.2 years, Child-Pugh class A&B cirrhosis (n=133 and 27, respectively), mostly hepatitis C (96.3%), with BCLC-A&B (n=74 and 86, respectively). RTR was present in 82 patients. Variables associated with poor OS: baseline lower serum albumin and platelet count, besides follow-up absent radiologic tumor response, an increase in AST > 25%, an increase in Child-Pugh score, and a fall in platelet count fall ≥ 10,000/mL3 before TACE2. By multivariate analysis, ART score parameters and platelet count fall were independent predictors of poor survival. RTR absence had the higher risk of mortality by 3.12 times than responding tumors. ART score subgroups (≤ 1.5 and ≥ 2.5 points, 81 and 79 patients, respectively) had no significant relation to OS (22.3 vs 16.7 months; P=0.07). On modifying the ART score by adding 3 points for fallen platelet count ≥ 10,000/mL3 (ART-P score), 113 patients scored 0– 5 and 47 scored ≥ 5.5 with a median OS of 22 vs 11.2 months, respectively (P=0.01). Conclusion: ART score could not identify patients who will benefit from TACE retreatment in intermediate-stage HCC patients, and the addition of platelet count reduction (P-ART) could improve its prognostic ability.

11 May 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
MUMei Ran Abellona U
Mei Ran Abellona U
ESEric Yi-Liang Shen
Eric Yi-Liang Shen
CCCaroline Cartlidge
Caroline Cartlidge
AAAlzhraa Alkhatib
Alzhraa Alkhatib
MTMark R. Thursz
Mark R. Thursz
STSimon David Taylor-Robinson
Simon David Taylor-Robinson
This review aims to develop an appropriate review tool for systematically collating metabolites that are dysregulated in disease and applies the method to identify novel diagnostic biomarkers for hepatocellular carcinoma (HCC). Studies that analyzed metabolites in blood or urine samples where HCC was compared with comparison groups (healthy, precirrhotic liver disease, cirrhosis) were eligible. Tumor tissue was included to help differentiate primary and secondary biomarkers. Searches were conducted on Medline and EMBASE. A bespoke “risk of bias” tool for metabolomic studies was developed adjusting for analytic quality. Discriminant metabolites for each sample type were ranked using a weighted score accounting for the direction and extent of change and the risk of bias of the reporting publication. A total of 84 eligible studies were included in the review (54 blood, 9 urine, and 15 tissue), with six studying multiple sample types. High-ranking metabolites, based on their weighted score, comprised energy metabolites, bile acids, acylcarnitines, and lysophosphocholines. This new review tool addresses an unmet need for incorporating quality of study design and analysis to overcome the gaps in standardization of reporting of metabolomic data. Validation studies, standardized study designs, and publications meeting minimal reporting standards are crucial for advancing the field beyond exploratory studies.

26 November 2025
Verified
Other
Open access
MUMei Ran Abellona U
Mei Ran Abellona U
ESEric Yi-Liang Shen
Eric Yi-Liang Shen
CCCaroline Cartlidge
Caroline Cartlidge
AAAlzhraa Alkhatib
Alzhraa Alkhatib
MTMark R. Thursz
Mark R. Thursz
STSimon David Taylor-Robinson
Simon David Taylor-Robinson
Supplementary Data from Optimized Systematic Review Tool: Application to Candidate Biomarkers for the Diagnosis of Hepatocellular Carcinoma

1 June 2026 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
AAAlzhraa Alkhatib
Alzhraa Alkhatib
AGAsmaa Gomaa
Asmaa Gomaa
WAWael Abdel-Razek
Wael Abdel-Razek
Background and Aim: Hepatocellular carcinoma (HCC) is the leading cause of cancer-related mortality in Egypt. The model for end-stage liver disease (MELD) score is the standard for prioritizing liver transplantation (LT) candidates but often underestimates hepatic biosynthetic failure in patients with compensated cirrhosis. This study evaluated the utility of an integrated “MELD-ALBI” classification to refine risk stratification in patients undergoing living donor liver transplantation (LDLT). Patients and Methods: This retrospective study included 76 adult patients with HCC who underwent LDLT between 2010 and 2021. Patients with early postoperative mortality (< 1 month) were excluded. An integrated model was developed stratifying patients into three classes: Class 1 (low risk): ALBI grade 1, or ALBI grade 2 with MELD < 12; Class 2 (intermediate risk): ALBI grade 2 with MELD ≥ 12; and Class 3 (high risk): ALBI grade 3. Results: The integrated model achieved a numerically higher diagnostic performance for predicting 1-year mortality (AUC=0.625) compared to MELD (AUC=0.611) or ALBI (AUC=0.593). Kaplan-Meier analysis showed significantly superior survival for Class 1 compared to Class 2 (P=0.029). In univariate Cox regression, Class 2 was associated with a threefold increase in mortality risk compared to Class 1 (HR 3.22, 95% CI 1.05– 9.90, P=0.041), whereas survival outcomes for Class 2 and Class 3 were statistically comparable (P=0.27). In multivariate analysis adjusted for age, Class 2 maintained a high hazard ratio (HR 2.59), though statistical significance was attenuated (P=0.101). Conclusion: The integrated MELD-ALBI classification identifies a “hidden high-risk” subgroup (Class 2) underserved by standard allocation. We propose assigning exception “Z-points” to these patients to align their priority with biological urgency. This framework offers a potential model for refining allocation.

26 November 2025
Verified
Other
Open access
MUMei Ran Abellona U
Mei Ran Abellona U
ESEric Yi-Liang Shen
Eric Yi-Liang Shen
CCCaroline Cartlidge
Caroline Cartlidge
AAAlzhraa Alkhatib
Alzhraa Alkhatib
MTMark R. Thursz
Mark R. Thursz
STSimon David Taylor-Robinson
Simon David Taylor-Robinson
Supplementary Data from Optimized Systematic Review Tool: Application to Candidate Biomarkers for the Diagnosis of Hepatocellular Carcinoma